| 臺大學術典藏 |
2022-04-07T01:43:07Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen C.-T.; TSUNG-HAO LIU; Shao Y.-Y.; Liu K.-L.; Liang P.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-03-15T05:39:32Z |
The impact of diabetes mellitus on prognosis of early breast cancer in Asia
|
WEI-WU CHEN; Shao Y.-Y.; Shau W.-Y.; Lin Z.-Z.; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2022-03-08T03:44:03Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:20Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-23T02:12:19Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; CHIEN-HUNG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; CHIEN-HUNG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
YING-CHUN SHEN; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; ANN-LII CHENG; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-14T07:10:49Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; YUNG-MING JENG; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-14T07:10:48Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; YUNG-MING JENG; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-07T03:29:06Z |
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; Lee J.-M.; Hsu C.; CHIH-HUNG HSU; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-02-07T03:29:05Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-02-07T03:29:05Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; CHIH-HUNG HSU; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-07T03:29:05Z |
An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma
|
Shao Y.-Y.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-02-07T03:29:05Z |
Solving the deficit of cancer pain management skills by education programs
|
Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; Lu L.-C.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-02-07T03:29:04Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-07T03:29:03Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; CHIH-HUNG HSU; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-07T03:29:03Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:36Z |
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; Lee J.-M.; CHIUN HSU; Hsieh C.-H.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; CHIUN HSU; Hsieh C.-H.; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; CHIUN HSU; Hsieh C.-H.; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
